BCMA CAR-T cell therapy / Xuzhou Medical University - LARVOL DELTA

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C group 5 member D CAR T-cell therapy. (PubMed, Haematologica) - "In this study, 20 subjects with RRMM after a prior anti-GPRC5D CAR T-cell therapy received BCMA-targeted CAR T-cell therapy as a salvage treatment. Fourteen subjects (78%) had cytokine release syndrome (grade ≥3, n=1). In conclusion, anti-BCMA CAR T-cell therapy was effective for RRMM after failing an anti-GPRC5D CAR T-cell therapy, and the safety profile was acceptable."

Journal • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Oncology

A proliferation-inducing ligand enhances the anti-tumor effect of BCMA CAR T-cell through inhibition of soluble BCMA. (PubMed, Biochim Biophys Acta Mol Basis Dis) - "In murine xenotransplant myeloma models, giving APRIL during the first week after infusion of BCMA CAR T-cells increased IFNγ-positive CAR T-cells in the tumor tissues, and enhanced the anti-tumor effect of CAR T-cell. In conclusion, APRIL counteracted the actions of sBCMA in BCMA CAR T-cell-mediated binding and killing of myeloma cells which might contribute to the efficacy of BCMA CAR T-cell therapies."

Journal • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation • IFNG

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Equecabtagene Autoleucel (Eque-cel, CT103A) in Fumanba-1 (ASH 2023) - P1/2 | "Pts who had progressed on previous BCMA CAR-T cell therapy were not included in this analysis. Based on our descriptive analysis, pts receiving eque-cel achieved MRD negativity irrespective of their high-risk cytogenetics, extramedullary disease, number of prior LOT and performance status. Presence of high tumor burden at baseline, and prior triple-class exposure might be factors that impact achievement of sustained MRD negativity. These data suggest that while eque-cel is effective for a broad range of pts, specific pt and disease characteristics may be associated with sustained MRD negativity and better long-term outcomes."

Clinical • IO biomarker • Minimal residual disease • Residual disease • Hematological Malignancies • Multiple Myeloma • Oncology

ASCTvsCAR-T: CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients? (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Xuzhou Medical University

New P2 trial • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible (clinicaltrials.gov) - P=N/A | N=35 | Not yet recruiting | Sponsor: Xuzhou Medical University

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation